

| | | |
|--|--|--|
| Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93) | | ATTORNEY'S DOCKET NUMBER GM50049 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/009315 |
| INTERNATIONAL APPLICATION NO. PCT/US00/12103 | INTERNATIONAL FILING DATE 04 May 2000 | PRIORITY DATE CLAIMED 10 May 1999 |
| TITLE OF INVENTION Methods for Producing Modified Nucleic Acid Molecules | | |
| APPLICANT(S) FOR DO/EO/US Alison F. CHALKER, David J. HOLMES, Robert Dwayne LUNSFORD, and James Yigong GE | | |

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☒ Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/US00/12103, filed 04 May 2000, which claims benefit from the following Provisional Application: 60/133,391, filed 10 May 1999.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ An Abstract on a separate sheet of paper.
19. ☒ Other items or information: Sequence Listing in Computer-Readable Format; Paper Copy of Sequence Listing; Statement to Support

J007 PCT/PTO 05 NOV 2001

| | | | | | |
|--|------------------|---|---------------------|---------------------------------|----|
| US APPLICATION NO. (if known see 37 CFR 1.50) 10/009315 | | INTERNATIONAL APPLICATION NO. PCT/US00/12103 | | ATTORNEYS DOCKET NO. GM50049 | |
| 20. [X] The following fees are submitted: | | | | CALCULATIONS PTO USE ONLY | |
| Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)): | | | | | |
| Search Report has been prepared by the EPO or JPO\$890.00 | | | | | |
| International Preliminary Examination Fee paid to USPTO (37 CFR 1.492)\$710.00 | | | | | |
| No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00 | | | | | |
| Neither International Preliminary Examination Fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00 | | | | | |
| International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$100.00 | | | | \$100.00 | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | | | \$100.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | \$0.00 | |
| Claims | Number Filed | Number Extra | Rate | | |
| Total claims | 32 - 20 = | 12 | 12 x \$18.00 | \$216.00 | |
| Independent claims | 4 - 3 = | 1 | 1 x \$84.00 | \$84.00 | |
| Multiple dependent claims (if applicable) | | | + \$280.00 | \$0.00 | |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$400.00 | |
| Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). | | | | \$ | |
| SUBTOTAL = | | | | \$400.00 | |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) + | | | | \$ | |
| TOTAL NATIONAL FEE = | | | | \$400.00 | |
| | | | | Amount to be refunded | \$ |
| | | | | charged | \$ |

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **\$400.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE


Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-4478

Facsimile (610) 270-5090



SIGNATURE

Edward R. Gimmi

NAME

38,891

REGISTRATION NO.

METHODS FOR PRODUCING
MODIFIED NUCLEIC ACID MOLECULES

Field of the Invention

- 5 The invention relates generally to methods for generating modified nucleic acid molecules, and more particularly, to the use of polymerase chain reaction to generate gene knockouts and nucleic acid fusion molecules.

Background of the Invention

- 10 There are a variety of reasons which make the modification of nucleic acid sequences, particularly genes, desirable. The classical strategy for gene disruption requires the isolation of a gene and digestion with restriction enzymes [R. Rothstein, *Methods Enzymol.*, **101**:202-211 (1983)]. However, the use of restriction enzymes to digest the DNA fragments sometimes makes it difficult to construct appropriate
- 15 fragments disrupted by a marker DNA. To overcome this problem, several methods utilizing polymerase chain reaction (PCR) for constructing such deletions have been developed. However, it is still necessary to isolate the DNA fragment of interest, or to use a variety of complex steps [D.C Amberg *et al*, *Yeast*, **11**:1275-1280 (1995); A. Wach *et al*, *Yeast*, **10**:1793-1808 (1994); A. Wach, *Yeast*, **12**:259-265 (1996)].
- 20 One recently described method describes a strategy for constructing gene disruption cassettes by means of PCR and ligation. See, J. Nikawa and M. Kawabat, *Nucleic Acids Res.*, **26**(3):860-861 (1998). In a first step, two separate regions of a target gene are PCR amplified with primers specific for the target sequence and genomic DNA as a template. Secondly, the two PCR products are ligated with a
- 25 DNA fragment of a marker gene through two separate reactions. The ligated fragments are then PCR amplified separately. Following amplification the PCR amplified fragments are mixed, denatured, annealed, and extended with DNA polymerase. Finally, the product is PCR amplified with the outermost primers.
- 30 Despite these recent advances, there remains a need for methods for modifying nucleic acid molecules which are more efficient, yet permit precise engineering at the target site.

Summary of the Invention

The method of the invention provides a simple method for precisely generating a modified nucleic acid molecule to contain a deletion and/or an
5 insertion. Advantageously, this method does not require ligation and is well suited for use in automated formats, including high throughput formats.

In one aspect the invention provides a three-stage method for inserting a cassette into a nucleic acid molecule to produce a modified nucleic acid molecule fusion without requiring ligation. In the first stage, the method involves amplifying
10 two separate regions of a selected nucleic acid molecule and a cassette. The two regions of the nucleic acid molecule have nucleotide sequences flanking a site in the molecule targeted for disruption, whereby the amplification produces a first amplification product of nucleotide sequences upstream of the target site and a second amplification product of nucleotide sequences downstream of the target site.
15 The cassette has sequences at its 5' and 3' ends which overlap with sequences of the two regions of the nucleic acid molecule. In the second stage, the amplified cassette product is mixed separately with the first or second amplification products resulting from amplification of the nucleic acid molecule. The cassette and first amplification product are amplified by PCR, thereby forming a first fusion product consisting of
20 the first amplification product fused to the 5' end of the first strand of the cassette. The cassette is also mixed with the second amplification product and this mixture is amplified to form a second fusion product consisting of the second amplification product fused to the 3' end of the first strand of the cassette. In a third stage, the first and second fusion products are mixed and amplified by PCR, thereby producing
25 a modified nucleic acid molecule comprising the cassette in the target site of the selected nucleic acid molecule. Desirably, the resulting modified nucleic acid molecule is amplified via polymerase chain reaction.

In another aspect, the invention provides a novel method for performing amplifying selected sequences by PCR, which is particularly well suited for use in
30 the stage three of the method of the invention. In this method, a mixture containing the fusion products prepared according to stage 2 of the method of the invention is

heated for about 5 minutes in the absence of polymerase or primers at about 94EC, cooled to 50EC over about 30 minutes, at which temperature it is maintained for about 5 minutes or longer. A thermostable polymerase is then added to the mixture, which is heated to about 72EC for about 5 minutes, and mixed with a forward primer P1 for the first region and a reverse primer P4 for the second region. The resulting mixture is then amplified using PCR to produce a modified nucleic acid molecule comprising the first and second regions of the nucleic acid sequence flanking the cassette.

In a further aspect, the invention provides a two stage method of producing a modified nucleic acid molecule without ligation. The method involves producing two separate regions of a nucleic acid molecule and a cassette as in stage 1 of the three stage method of the invention. Thereafter, the three products are mixed and subjected to amplification by PCR, as described in the aspect above. Thus, this embodiment of the invention permits elimination of stage 2 of the three-stage method.

In yet a further aspect, the invention provides modified nucleic acid sequences produced using the method of the invention.

In yet another aspect, the present invention provides a method of high throughput preparation of disrupted *Streptococcus* DNA sequences without ligation. This method involves mixing (a) a nucleic acid molecule comprising *Streptococcus* DNA sequences comprising a first region upstream of a site in the *Streptococcus* DNA targeted for disruption and a second region downstream of the target site, said first and second region each having a first and second end, (b) a cassette comprising at one end, nucleotide sequences which overlap with nucleotides at the second end of the first region, and at its other end, nucleotides which overlap with nucleotides of the first end of the second region, and (c) primers for the first and second regions in each of the wells of a plate containing a plurality of reaction wells. This mixture is then subjected to PCR, thereby amplifying the first and second regions of the selected *Streptococcus* DNA sequences. The cassette and the amplified first and second regions of the *Streptococcus* DNA sequences are then mixed and subjected to polymerase chain reaction to produce a nucleic acid fusion molecule comprising the

first and second regions of the Streptococcus DNA sequence flanking the cassette.

Other aspects and advantages of the invention will be readily apparent from the detailed description of the invention.

5 **Brief Description of the Drawings**

Fig. 1 is a flow diagram illustrating the use of the three-stage PCR method of the invention to construct a modified nucleic acid molecule containing a selected cassette.

10 **Detailed Description of the Invention**

The present invention provides a novel method for rapidly generating modified nucleic acid molecules, wherein the modification involves insertion of a cassette and/or deletion of desired sequences. This method eliminates the ligation steps required in known methods for generating knock-out genes, and permits
15 precise targeting of the site in the nucleic acid molecule for insertion of a cassette or deletion of sequences. Further, the method of the invention is readily adapted for use in high throughput screening.

Thus, the invention provides a method for modifying a nucleic acid molecule at a predetermined target site by insertion and/or deletion of nucleic acid sequences
20 in the absence of ligation. The method of the invention may be used to make unmarked deletions by using primers having an overlap region. More desirably, the method of the invention is used in the production of a modified nucleic acid molecule which is a nucleic acid-cassette fusion. Optionally, this nucleic acid-cassette fusion may be a knock-out construct.

A knock-out construct refers to a modified nucleic acid molecule in which
25 the function of a selected gene in the molecule has been disrupted, either by its deletion (either partial or fully) or by the insertion of a cassette which eliminates its function. In certain instances, a knock-out construct may have both a deletion and an inserted cassette.

As used herein, a nucleic acid molecule is composed of nucleotide sequences
30 of RNA or DNA. The RNA or DNA may be double- or single stranded and may be

readily selected from the different subtypes of RNA (e.g. mRNA or tRNA) or DNA (e.g., genomic, chromosomal, or cDNA). Optionally, the nucleotides of these molecules may contain modifications, e.g., labels which are known in the art, methylation, "cap", substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications. A particular advantage of the method of the invention is that it can readily be applied to nucleic acid molecules regardless of whether they are linear or circular, e.g., plasmids. The nucleic acids used in the method of the invention may be obtained from any suitable source, including, for example, viruses, plasmids, yeast, gram positive and gram negative bacterial, eukaryotic cells, and the like. Currently, preferred sources of bacterial nucleic acids include the gram-positive *Streptococcus* and *Staphylococcus* and the gram negative *Haemophilus influenzae*. However, selection of the nucleic acid molecules is not a limitation of the present invention.

A target site is a location within a nucleic acid molecule or sequence into which a cassette is to be inserted or from which sequences are to be deleted. Suitably, a target site may be composed of two nucleotides, between which an insertion is to be made, or a group of nucleotides, e.g., from two to ten bases in length which are to be deleted and/or into which the cassette is to be inserted. In certain embodiments (e.g., where deletions are to be made), the target site may be larger than 50 bases. In these embodiments, the target site may range from 50 bp to 5000 bp, 500 bp to 3000 bp, 1000 bp to 2500 bp, or other suitable sizes within these ranges. It is not essential that the target site be a coding sequence. In one embodiment, the target sequence may be selected particularly for use in essentiality testing or expression studies.

As used herein, a "cassette" is a nucleic acid sequence targeted for insertion into the target site of nucleic acid molecule and/or for fusion with two regions of the nucleic acid molecule. Such cassettes may be composed of single or double-stranded sequences, and may be linear or circular. While the size of a cassette useful in the invention is not a limitation, it is generally at least 10 nucleotides in length and as large as about 5000 nucleotides in length. Preferably, the nucleic acid sequence is a DNA sequence which performs some function. For example, the

cassette may be readily selected from among known marker genes, including, e.g., antibiotic resistance genes (e.g., erythromycin, tetracyclines, and chloramphenicols), reporter genes including those which are colorimetrically detectable, regulatory sequences including promoters, terminators, operators, and the like, and other functional DNA sequences, e.g., sequences encoding therapeutic or antigenic proteins. Alternatively, the cassette may be an oligonucleotide which introduces one or more base pair changes into the nucleic acid molecule to produce a desired effect in the resulting modified nucleic acid molecule. In still another alternative, the cassette may simply be a non-functional DNA sequence which is inserted to interrupt translation and expression of a protein encoded by a sequence located downstream of the target site. The cassettes used in the invention are engineered to contain sequences at the 5' and 3' end which overlap with (i.e., are identical to) sequences of the regions of the nucleic acid molecule flanking the target site. Thus, a cassette of the invention composed of double-stranded DNA would have a first strand with, at its 5' end, nucleotide sequences which overlap with nucleotides of a stand of the upstream region and, at its 3' end, nucleotide sequences which overlap with nucleotides of a strand of the downstream region. The region of overlap in sequences is between about 10 nt to about 50 nt in length, and preferably about 15 nt to about 35 nt, and most preferably about 20 nt in length. The cassettes useful in the invention may be readily obtained by a variety of convention methods, including genetic engineering methods and chemical synthesis.

As used herein the term "upstream region" refers to those sequences of nucleic acid which are located 5' to the target site, with reference to the coding strand of the nucleic acid molecule. However, the upstream region need not be composed of sequences which encode a desired protein, peptide or other gene product. Where the target site is located within an open reading frame (ORF), the upstream region preferably contains sequences flanking the targeted ORF. Suitably, where the modified nucleic acid molecule is to be a knock-out construct, the upstream region contains sufficient homology to mediate homologous recombination between the modified nucleic acid molecule and the non-disrupted gene in a host cell into which the modified nucleic acid molecule is transformed. Generally, a length of about 100

nt to about 1000 nt. and preferably, at least about 500 nt, of homologous sequences is considered sufficient. Preferably, these "homologous sequences" contain exact (i.e., 100%) identity of sequences. However, the "homologous sequences" may contain some degree of nonidentity. Where there is some degree of non-identity, the sequences suitably have at least 95% identity, more preferably 97% identity, and most preferably 98-99% identity. In other embodiments, particularly where homologous recombination is not desired following transformation of a host cell, the size of the upstream region may be readily determined by one of skill in the art. For example, the upstream region may be as small as about 100 bp and as large as 500 kb, or more.

The term "downstream region" refers to those sequences of nucleic acids which are located 3' to the target site, with reference to the coding strand of the nucleic acid molecule. As with the upstream region, the downstream region need not be composed of coding sequences; and, where the target site is located within an ORF, the downstream region preferably contains sequences flanking the targeted ORF. Suitably, the size of the downstream region is determined by the factors described above with respect to the upstream region. However, it will be understood that the sizes of the downstream region and upstream region may be selected independently of one another.

It should be noted that although the discussion refers in many locations to double-stranded DNA for purposes of convenience, it will understand that the method of the invention is useful with single-stranded nucleic acid sequences. Further, it will be recognized that even in situations where the nucleic acid molecule and the insertion cassette are double-stranded, single-stranded DNA may be added to the PCR mixture for use in obtaining the desired amplification product(s).

As known in the art, "homology" or "identity" means the degree of sequence relatedness between two polypeptide or two polynucleotide sequences as determined by the identity of the match between two lengths of such sequences. Both identity and homology can be readily calculated by methods extant in the prior art [See, e.g., COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, (1988); BIOCOMPUTING: INFORMATICS AND

GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, (1993);
COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and
Griffin, H.G., eds., Humana Press, New Jersey, (1994); SEQUENCE ANALYSIS IN
MOLECULAR BIOLOGY, von Heinje, G., Academic Press, (1987); and
5 SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M
Stockton Press, New York, (1991)]. While there exist a number of methods to
measure identity and homology between two polynucleotide sequences, the terms
"identity", "similarity" and homology are well known to skilled artisans [H. Carillo
and D. Lipton, SIAM J. Applied Math., 48:1073 (1988)]. Methods commonly
10 employed to determine identity or homology between two sequences include, but are
not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed.,
Academic Press, San Diego, 1994, and H. Carillo and D. Lipton, SIAM J. Applied
Math., 48:1073 (1988). Preferred methods to determine identity or homology are
designed to give the largest match between the two sequences tested. Methods to
15 determine identity and similarity are codified in computer programs. Preferred
computer program methods to determine identity and homology between two
sequences include, but are not limited to, the algorithm BESTFIT from the GCG
program package [J. Devereux et al., Nucl. Acids Res., 12(1):387 (1984)], the
related MACVECTOR program (Oxford), and the FASTA (Pearson) programs,
20 which may be used at default settings or modified settings such as determined to be
suitable by one of skill in the art.

I. Three Stage PCR

It will be readily recognized by one of skill in the art that the methods of the
25 invention may be readily performed using a high throughput format, i.e., the
reactions may be performed on a plate containing a multiplicity of reaction
chambers, e.g., 96, 384, or 1536 wells. Such plates are readily available from a
variety of sources. However, the reactions may similarly be performed in a variety
of other suitable reaction vessels, e.g., tubes. Selection of the reaction vessel is not a
30 limitation of the present invention.

Following selection of the target site within the nucleic acid molecule,

primers are obtained for specifically amplifying the upstream and downstream regions flanking the target site. Such primers may be readily generated, e.g., by chemical synthesis or other suitable means, based on the knowledge of the sequences of the nucleic acid molecule, particularly in the area of the target site. Currently, it is preferable for all of the primers described for use in the method of the invention to contain 40-50% G+C content to facilitate the PCR reaction. However, it is possible to vary the G+C content within the range of 35% to about 55% of the primer. In one particularly desirable embodiment, a set of two primers is generated for each of the two regions flanking the target site.

Thus, a forward primer, P1, and a reverse primer, P2, for the region upstream of the target site are obtained from commercial sources or generated using conventional techniques. P1 is about 20 nt to about 30 nt, and more preferably, about 20 nt in length. Optionally, this primer may contain restriction sites for use in molecular cloning after generation of the final fusion product. The P1 primer is complementary to the 5' end of a first strand of the region of the nucleic acid molecule upstream of the target site. Most preferably, the P1 primer targets the extreme 5' end of the first strand. However, it may target sequences very distal (e.g., several nucleotides from the extreme 5' end) or sequences that use some of the actual coding region for homology, provided that a sufficient portion of the target site is deleted or disrupted to inactivate its function. P2 is about 30 nt to about 50 nt, and more preferably, about 40 nt in length. In addition to containing reverse sequences of complementarity for the region upstream of the target site, this primer is designed to contain a tail with reverse complementarity to the 5' end of the cassette. This tail is about 20nt to 30 nt, and preferably 20 nt in length. Generally, the P2 primer is complementary to the 5' end of a second strand (having reverse complementarity to the first strand) immediately upstream (i.e., at the next nt base) of the target site. (Desirably, where coding sequences are targeted, the first strand may be a sense strand and the second strand may be an anti-sense strand.)

Similarly, a forward primer, P3 and a reverse primer, P4, are obtained for the region downstream of the target site. P3 contains a nt tail which has a region of forward polarity to the 3' end of the cassette (i.e., is complementary) and forward

sequences for homology to the sequences down-stream of the target site. Suitably, the P3 primer is complementary to the 5' end of a first strand immediately upstream of the target site. The tail of P3 may be about 20 nt to 30 nt. and preferably 20 nt in length. P4 is about 20 nt to about 30 nt. and more preferably, about 20 nt in length.

- 5 Optionally, this primer may contain restriction sites for use in molecular cloning after generation of the modified nucleic acid molecule which is the final fusion product. P4 amplifies the sequences at the 5' end of the second strand (having reverse complementarity to the first strand) of the downstream region of the nucleic acid molecule. Most preferably, the P4 primer targets the extreme 5' end of the
10 second strand. However, it may target sequences very distal (e.g., several nucleotides from the extreme 5' end) or sequences that use some of the actual coding region for homology, provided that a sufficient portion of the target site is deleted or disrupted to inactivate its function.

- In certain situations, it may be desired not only to introduce a cassette into a
15 target site, but also to delete sequences from the nucleic acid molecule in order to do so. In such situations, the target site is a short sequence as defined above rather than a location between two nucleotide bases and the primers are designed to amplify the regions upstream and downstream of the sequences of the target site. Similarly, the cassette is designed to contain sequences overlapping with the nucleotide bases
20 flanking either side of the target sequence. Thus, performance of the method steps described herein will result in a modified nucleic acid molecule containing an upstream region fused to the cassette which is fused to a downstream region, and further containing a deletion of the target sequences of the nucleic acid molecule.

- For purposes of illustrating three-stage PCR, reference throughout the
25 following discussion may be made to Fig. 1. However, other embodiments of the methods beyond that illustrated in the figure are described below.

A. Stage 1 Amplification

- In one desired embodiment, two separate regions of the nucleic acid molecule flanking the target site are produced using the P1/P2 for the upstream
30 homology and P3/P4 for the downstream homology. This amplification is performed using PCR.

The PCR steps performed in the method of the invention are performed with a thermostable DNA or RNA polymerase and a polymerase having 3'-5' exonuclease activity to remove non-template bases at the 3' and 5' ends. For example, an example of a particularly suitable thermostable DNA polymerase is *Taq* DNA polymerase. The native enzyme may be purified from *Thermus aquaticus* or genetically engineered from the enzyme may be synthesized or obtained from a commercial source (e.g., as AmpliTaqTM). *Taq* is particularly desirable because it carries 5' polymerization-dependent exonuclease activity. Thus, if this polymerase is selected, it is only necessary to include in the reaction mixture a proof-reading polymerase with 3' exonuclease activity. Suitably, high fidelity polymerases are also desirable because they possess 3' and/or 5' exonuclease activity. Examples of high fidelity polymerases include *Pfu* (has 3' proof-reading activity), *Pvu* (has 5' proof-reading activity), *Vent.*, *Deep Vent.*, *Hot Tub.*, *Tfl.*, and *Thr* polymerases. However, other suitable polymerases may be selected and obtained from a variety of commercial sources (e.g., Stratagene). Alternatively, other DNA polymerases may be readily selected and 5' and/or 3' exonucleases added if these functions are not provided by the selected polymerase. Such polymerases and exonucleases may be readily selected by one of skill in the art and obtained from a variety of sources. Reaction conditions are as specified by the enzyme supplier with extension times adjusted for the expected product size. See, also, e.g., Sambrook et al, "Molecular Cloning: A Laboratory Manual", 2nd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY (1989), ch. 14.2-14.4 for a general discussion of suitable PCR reagents, buffers, and conditions.

The upstream and downstream regions of the nucleic acid molecule may be generated in a single reaction, or in separate reactions, as desired. Desirably, the final products are purified to homogeneity. This purification can be performed using conventional techniques, including spin dialysis performed in microconcentrators or polyacrylamide or agarose gel electrophoresis. See, Sambrook et al, cited above. An example of a suitable system which is commercially available includes Qiagen's affinity matrix purification systems. However, other commercially available systems may be readily selected.

Suitably, the cassette is also amplified via PCR using a proof-reading polymerase as described above for the upstream and downstream regions. The forward primer, R1, and reverse primer, R2, for the cassette are obtained using conventional techniques such as those described above. These primers are generally
5 about 20 to about 30 nt in length. Optionally, the cassette may be amplified in a reaction which also contains the upstream region and downstream region. Alternatively, the cassette is amplified in separate reactions with the upstream region or the downstream region. In yet another alternative, the cassette is amplified prior to mixture with either the upstream or downstream region. Following amplification,
10 the final product is purified to homogeneity as described herein.

B. Stage 2 Amplification

The product resulting from amplification of the cassette is mixed with an approximately equivalent amount of the product of the amplification of the upstream region or the product of the amplification of the downstream region. For a
15 typical PCR reaction, the amount of each amplification product mixed is about 0.1 µg. However, these amounts may be adjusted, e.g, from as low as 0.05 µg to as high as about 0.5 µg to about 1.0 µg. In these separate PCR reactions using proof-reading polymerases as described above for stage 1 amplification, the appropriate primers are used. More particularly, for the mixture containing the upstream region
20 and the cassette, primers P1 and R2 are used. The resulting product is a fusion product having the 3' end of a first strand of the upstream region fused to the 5' end of the first strand of the cassette. For the mixture containing the cassette and the downstream region, primers R1 and P4 are used. The resulting fusion product is the
25 3' end of the first strand of the cassette fused to the 5' end of the first strand of the downstream region. Preferably, the resulting fusion products are purified to homogeneity.

C. Stage 3 Amplification

The purified fusion products generated as described above are then mixed and subjected to PCR in order to generate a modified nucleic acid molecule
30 which contains the cassette in the target site of the selected nucleic acid molecule, flanked by the upstream region and the downstream region. While this PCR may be

performed as above. using convention PCR steps with a proof-reading polymerase, it has been found that a modification to these standard techniques provides better yield.

Thus, the third amplification stage involves the following procedure.

A mixture containing the products to be amplified, e.g., the two fusion products
5 obtained from stage 2 amplification, is heated in the absence of polymerase or primers. Suitably, this may be performed in a standard buffering solution, e.g., 50 mM KCl, 10 mM Tris.Cl and 1.5 mM MgCl₂. The heating step is performed for about 2 to about 8 minutes, preferably about 5 minutes, to a temperature of about 85EC to about 96EC, and preferably about 94EC. The heated mixture is then taken
10 to a temperature of about 45EC to 55EC, and most preferably about 50EC, over an extended period of time. Most suitably, the cooling takes place over at least about 20 minutes, and preferably over at least 30 minutes. Thereafter, the mixture is maintained at about the same temperature, e.g., at about 50EC, for at least about 5 minutes. However, this temperature may be maintained for a longer period of time
15 such as an hour, several hours, or overnight, if required for convenience.

Following this incubation at 50EC, a thermostable polymerase is added to the mixture. A suitable RNA or DNA polymerases may be readily selected. See, discussion of polymerases in section relating to stage 1 amplification. The mixture containing the products for amplification and the polymerase (and
20 exonucleases) are heated to about 55EC to about 75EC for about 3 to about 20 minutes. Preferably, this heating is performed at about 72EC for about 5 minutes. The primer P1 for the upstream region and the primer P4 for the downstream region are then added to the mixture which is subjected to a standard 30 cycles of PCR with an extension time appropriate for the expected full-length product.

25 The resulting full-length product is a modified nucleic acid molecule containing the upstream region fused to the cassette which is fused to the downstream region. Optionally, the product is purified to homogeneity prior to further amplification. Alternatively, the product may be subjected to further amplification via PCR prior to purification. Thus, the method of the invention
30 provides a modified nucleic acid molecule containing the cassette in the target site which is flanked by the upstream and downstream region.

Optionally, the plates or tubes containing the final product, i.e., modified nucleic acid molecule, may be stored in the freezer (e.g., at -80EC) while awaiting further testing. Where desired, the final product is purified using any of a variety of suitable means, e.g., agarose gel electrophoresis, and, optionally, a sample
5 may be sequenced to confirm the identity of the product.

II. Two-Stage PCR

In another embodiment, the method of the invention also permits one to produce a modified nucleic acid molecule, which does not require separate
10 generation of the upstream region/cassette and cassette/downstream region fusion products. In other words, stage 1 and stage 3 amplification are performed as described herein for the three-stage method, but stage 2 amplification is eliminated. As with the three-stage PCR embodiment of the invention, this method may be performed in a multi-well plate, a tube, or in any other suitable reaction vessel.

15 In such an embodiment, the upstream region, cassette and downstream region may be produced as described in stage 1 above. Briefly, P1/P2 are used for the upstream region of the nucleic acid molecule and P3/P4 for the downstream region of the nucleic acid, using PCR with a high fidelity polymerase possessing 3'-5' exonuclease activity. These regions contain sufficient homology to mediate
20 homologous recombination in a particular host cell. A fusion cassette, R is also amplified with R1 and R2. Reaction conditions are as specified by the enzyme supplier with extension times adjusted for the expected product size. Each final product is purified to homogeneity.

In the final stage of this embodiment of the method of the invention,
25 approximately equivalent amounts of the cassette, upstream region and downstream regions produced are mixed, and amplified as described for stage 3 amplification, using P1 and P4 to PCR amplify the final product. Reaction conditions are as specified by the enzyme supplier with extension times adjusted for the expected product size. The product is purified to homogeneity, and optionally, sequenced to
30 confirm its identity.

III. The Modified Nucleic Acid Molecules

Thus, the three-stage and two-stage PCR methods of the invention may be utilized to construct modified nucleic acid molecules useful for a variety of purposes. These modified nucleic acid molecules may be intermediate products useful for subsequent molecular cloning of a desired construct. For example, a modified nucleic acid molecule of the invention may be engineered to contain restriction sites which permit rapid insertion of a digestion fragment containing a desired portion of the modified nucleic acid molecule and the cassette into a pre-determined location in a desired plasmid or viral vector, or the like. In such an instance, the modified nucleic acid molecules are constructed using primers containing the appropriate restriction sites to facilitate this molecular cloning. Alternatively, the modified nucleic acid molecules generated according to the invention may represent a desired end-product, i.e., for testing or for therapeutic or vaccinal use.

15 A. Assay Formats

Suitably, the invention provides a method for generating modified nucleic acid molecules which are suitable for constructing gene knockouts for *in vitro* or *in vivo* testing of specific genes, and particularly for testing whether such specific genes are essential for a particular function. It may be desirable in these embodiments for the cassette inserted to contain a reporter or marker gene, as defined above. However, in other embodiments, the use of a gene encoding a therapeutic protein is desirable and assays are performed to determine the effect of expression of the therapeutic protein on a selected host cell.

In one embodiment, gene knockouts may be tested *in vitro* using a high throughput assay format. Suitably, the modified nucleic acid molecules containing the disrupted gene are constructed according to the three-stage or two-stage PCR method of the invention and contain a cassette with a marker gene. Thereafter, a suitable host cell which contains a functional gene corresponding to the gene disrupted in the modified nucleic acid molecule of the invention is added to each of the wells. For example, if the modified nucleic acid molecule is a plasmid or linear fragment containing sequences from *Streptococcus pneumoniae* with a

functional deletion in a selected gene, one may add *Strep. pneumoniae* cells to wells containing the modified nucleic acid molecules produced according to the present invention. The plates are then incubated under conditions which promote transformation of the cells with the modified nucleic acid molecules. Most preferably, the cells used are "pre-competent" and are grown through the competent phase in the presence of the knock-out constructs. Optionally, the competent phase may be induced by competence stimulating peptide (CSP). Thereafter, the plates are checked for the presence or absence of cell growth. Transformation of the cells is confirmed by detection of the marker. Where the presence of the marker is detectable, the absence of cell growth is an indication that the selected gene functionally deleted from the knockout is essential for cell growth. Positive cell growth indicates that the functionally deleted gene is non-essential for cell growth. A similar assay format may be used to determine the impact of a foreign gene on a selected host cell, where the modified nucleic acid construct of the invention contains a cassette encoding a heterologous gene product. Alternatively, the modified nucleic acid molecules of the invention may be used *in vivo* assays, many of which are known in the art. Selection of suitable *in vitro* and *in vivo* assays are not a limitation of the present invention.

In another embodiment, the method permits the rapid construction of fusion molecules encoding therapeutic or antigenic proteins for expression studies and the like. For example, this may provide a rapid method of generating vaccinal or therapeutic viral vectors, or modified bacterial vaccine candidates. In these embodiments, the cassette may include a transgene under the direction of regulatory sequences which direct its expression in a host cell. Thus, the cassette may be engineered to contain a promoter, enhancer, transcription initiation or termination sequences, efficient RNA processing signals such as splicing and polyadenylation signals (which may contain splice donor and acceptor sites), sequences that stabilize cytoplasmic mRNA, sequences that enhance translation efficiency (i.e., Kozak consensus sequence), sequences that enhance protein stability and, when desired, sequences that enhance protein secretion, as well as other regulatory and expression control sequences. In one embodiment, the method of the invention may be used to

place a chromosomal gene copy under the control of a regulatable promoter, or to place a foreign gene controlled by a regulatable promoter in a non-essential site on the chromosome. Thus, promoters may be constitutive or inducible or regulatable. Selection of suitable promoters and other vector elements are conventional and many
5 such regulatory and expression control sequences are available [see, e.g., Sambrook et al, and references cited therein at, for example, pages 3.18-3.26 and 16.17-16.27 and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989].

B. Pharmaceutical Compositions

10 The modified nucleic acid molecules of the invention may be useful for *in vitro*, *ex vivo*, or *in vivo* delivery of a transgene to a selected host cell. Alternatively, the modified nucleic acid molecules of the invention may be useful in pharmaceutical compositions for *ex vivo* or *in vivo* delivery of a transgene for
15 therapeutic or vaccinal purposes. Such pharmaceutical compositions contain the modified nucleic acid molecule produced according to the method of the invention formulated with a pharmaceutically acceptable carrier, such water, a saline solution, a vegetable oil, or mixtures thereof. Other suitable carriers may be readily selected by one of skill in the art and are not a limitation of the present invention. Still other
20 components customarily employed in the preparation of pharmaceutical compositions may be advantageously included, including, adjuvants, preserving agents, coloring agents, and the like.

Suitably, the molecules of the invention are combined with one or more pharmaceutically acceptable carriers, for examples, solvents, diluents and the like, and are administered in the form of sterile injectable solutions or suspensions
25 containing the molecules in an isotonic medium. Generally, the modified nucleic acid molecules of the invention are delivered in an amount of about 0.01 μ g to 100 mg per kg body weight. The molecules may be suspended in a carrier, as identified above, and delivered in doses of from about 1 mL to about 30 mL by any suitable route, including, without limitation, intravenous, intramuscular, subcutaneous, and
30 oral. The method of administration is not limited to the delivery routes specified herein. It is within the skill of one in the art to determine the appropriate dosage

regimen, taking into consideration such factors as the condition to be treated, the age, weight, sex and condition of the patient, and the like.

The following examples demonstrate product of several modified nucleic acid molecules using the methods of the invention. These examples are illustrative only and are not a limitation of the present invention.

Example 1 - Two-piece PCR method used to make an erythromycin-resistant knockout cassette which when transformed into *Streptococcus pneumoniae* demonstrated *fabH* essentially.

S. pneumoniae gene identified as *fabH*, primers to the gene sequence were designed follows. The bold underlined regions are complementary to R1 and R2 which in this experiment are designed to amplify up the *ermAM* erythromycin resistance gene; and the non-underlined regions are homologous to DNA sequences in or flanking *fabH*:

P1 [SEQ ID NO: 1] 5' TAAGGGGCTACATTGACCGAGTTC 3'
 P2 [SEQ ID NO: 2] 5' CCGCCATTCTTTGCTGTTTCGTTCCAGCTTTTGCCA
 TCAGTTTCT 3'
 P3 [SEQ ID NO: 3] 5' GGAAAGTTACACGTTACTAAAGGCTGGGGCACGCT
 CATTCTTACA 3' P4 [SEQ ID NO: 4] 5' TTTTCATAGTGCCTCCAACCTT3'
 P5 [SEQ ID NO: 5] 5' CTTATTTTACCCATGCCCTTGT3'
 P6 [SEQ ID NO: 6] 5' CAGGCCATCCCTCCTTGGAAAATA 3'
 R1 [SEQ ID NO: 7] 5' CGAAACAGCAAAGAATGGCGG 3'
 R2 [SEQ ID NO: 8] 5' CCTTTAGTAACGTGTAACCTTTC3'

The two-piece PCR reaction was performed using *S. pneumoniae* isolated chromosomal DNA as template. In separate PCR reactions, P1/ P2 were used to produce the upstream region and P3/P4 were used to produce the downstream region using PCR with Taq polymerase [AmpliTaq] and Pfu proof-reading polymerase. Reaction conditions were as specified by the enzyme supplier with extension times adjusted for the expected product size. The cassette was produced using a similar PCR reaction. Each final product was purified to homogeneity on an agarose gel column.

P1/P2 413bp

P3/P4 437bp

R1/R2 941bp

The Stage II purified modified nucleic acid molecule consisting of a *fabH* knockout construct was sequenced to confirm its identity and used to transform *S. pneumoniae* R6 competent cells was transformed using standard techniques. Briefly, the DNA was incubated with pre-competent cells, which are allowed to grow to permit phenotypic expression of the marker, and transformants identified following growth under selective conditions. No colonies were obtained after 3 attempts, indicating that the *fabH* gene is essential in *S. pneumoniae*.

Example 2 - Three-piece PCR method used to make an erythromycin-resistant knockout cassette which when transformed into *Streptococcus pneumoniae* demonstrated *fabH* essentiality.

In order to knockout the *S. pneumoniae* gene identified as *fabH*, primers to the gene sequence were designed as follows. The bold underlined regions are complementary to R1 and R2 which in this experiment are designed to amplify up the *ermAM* erythromycin *fabH*:

P1 [SEQ ID NO: 10] 5' TAAGGGGCTACATTGACCAGTTC 3'

P2 [SEQ ID NO: 11] 5' CCGCCATTCTTTGCTGTTTCGTTCCAGCTTTTGCC ATCAGTTTC 3'

P3 [SEQ ID NO: 12] 5' GGAAAGTTACACGTTACTAAAGGCTGGGGCACGC TCATTCTTAC3'

P4 [SEQ ID NO: 13] 5' TTTTCATAGTGCCTCCAACCTT3'

P5 [SEQ ID NO: 14] 5' CTTATTTTACCCATGCCCTTGTA 3'

P6 [SEQ ID NO: 15] 5' CAGGCCATCCCTCCTTGGAAAATA 3'

R1 [SEQ ID NO: 16] 5' CGAAACAGCAAAGAATGGCGG 3'

R2 [SEQ ID NO: 17] 5' CCTTTAGTAACGTGTAACCTTCC 3'

The three-piece PCR reaction was set up using *S. pneumoniae* isolated chromosomal DNA as template. The Stage I reactions were performed as described in Example 1, using the primers of this example. The product sizes were determined

by agarose gel electrophoresis:

P1/P2 413bp

P3/P4 437bp

R1/R2 941 bp

5 In Stage II, two separate PCRs were performed using Taq polymerase as in the first stage reaction. In a first PCR, 0.1 µg of each of the products from PCR of the cassette and the upstream region of *S. pneumoniae* were mixed and in a second PCR reaction, 0.1 µg of each of the products from PCR of the cassette and the downstream region of *S. pneumoniae* were mixed. For the upstream reaction, primers P1 and R2 were used. For the downstream reaction, primers R1 and P4 were used. The two resulting fusion products, i.e., upstream region/cassette and cassette/downstream region, were purified to homogeneity prior to Stage III.

15 Stage III was performed by mixing 0.5µg of each the upstream region/cassette and cassette/downstream region in a standard Taq polymerase PCR without polymerase or primers. The reaction was held for 5 minutes at 94EC, and then taken to 50EC over a ramp period of 30 minutes. The reactions was then held at 50EC for 5 minutes. During this time, 2.5 U of Taq polymerase was added, and the reaction was taken to 72EC for an extension time of 5 minutes. After this period, P1 and P4 are added, an the reaction was subjected to a standard 30 cycle PCR.

20 The Stage III purified *fabH* knockout cassette was sequenced to confirm its identity and used to transform *S. pneumoniae* competent cells. No colonies were obtained after 3 attempts, indicating that the *fabH* gene is essential in *S. pneumoniae*.

Similar methods may be used to assay the function of non-essential genes. Where the gene is non-essential, mutant colonies will be obtained. Southern blot analysis and diagnostic PCR reactions can be used to assay the band sizes following agarose gel electrophoresis.

Example 3 - Three-stage PCR method used to make a knockout cassette which was cloned into a *Staphylococcus aureus* plasmid for essentiality studies.

30 In order to knockout the *S. aureus* gene identified as *era*, primers to the gene sequence were designed as follows. The bold underlined regions are complementary

to R1 and R2 which in this experiment are designed to amplify the *ermC* erythromycin resistance gene; and the non-underlined regions are homologous to DNA sequences in or flanking *era*. The lower case bases represent thermal clamps (cgc) and recognition sites (ggatcc) for the restriction enzyme *Bam*HI used for

5 cloning purposes:

P1 [SEQ ID NO: 18] 5' cgcggatccTGTTGTAGATTTAGTGACCG 3'

P2 [SEQ ID NO: 19] 5' CGGGATACAAAGACATAATCTTCCTACATTGG
TCTACC 3'

P3 [SEQ ID NO: 20] 5' GTAAGTTAAGGGATGCATAATGGTTATGTTGAAG
10 ACCAAG 3'

P4 [SEQ ID NO: 21] 5' cgcggatccTCAGCTTGTGTGTCATTACC 3'

P6 [SEQ ID NO: 22] 5' ATCTTTAGAAGCCTCTTGCC 3'

R1 [SEQ ID NO: 23] 5' GATTATGTCTTTGTATCCCG 3'

R2 [SEQ ID NO: 24] 5' TTATGCATCCCTTAACCTAC 3'

15 The three-piece PCR reaction was set up as described in section B above using *S. aureus* WCUH29_c isolated chromosomal DNA as template. The Stage I reactions produced products of the predicted sizes as determined by agarose gel electrophoresis:

P1/P2 615bp

20 P3/P4 530bp

R1/R2 1234bp

The Stage III purified knockout cassette was cloned into pBluescript-*tetA* at the *Bam*HI site to produce pEra. pEra was introduced into *S. aureus* RN4220 by electroporation. Colonies were obtained that were dual Em^R and Tc^R, and
25 represented plasmid insertion cointegrants at the *era* locus. Diagnostic PCR products were obtained with:

R1/P6 1825bp

Indicating that the plasmid had integrated into the chromosome using the right flank (P3/P4) of homology with *era*.

30 A ϕ 11 bacteriophage lysate was prepared on the cointegrant strain, and the resulting transducing phage were used to infect WCUH29_c. Clones were selected

that were Em^R and Tc^S. These clones represented recombination events involving repeated sequences of the right flanking region generated during cointegrant formation, such that plasmid sequences were excised leaving behind an allelic exchange mutation of *era*. The predicted structure of the allelic exchange was

5 indicated by diagnostic PCR with:

P1/P4 2379bp

Since the *ermC* cassette introduced a new *NsiI* site into the *era* locus, the structure could be confirmed by Southern hybridization.

For genes that are essential for *in vitro* viability, Em^R and Tc^S clones would
10 not be recovered.

All publications cited in this specification are incorporated herein by reference herein. While the invention has been described with reference to a particularly preferred embodiment, it will be appreciated that modifications can be
15 made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method for inserting a cassette into a nucleic acid molecule to produce a nucleic acid-cassette fusion without requiring ligation, said method comprising the steps of:

(a) amplifying two separate regions of a selected nucleic acid molecule, wherein said regions comprise nucleotide sequences flanking a site in the molecule targeted for disruption, whereby the amplification produces a first amplification product of nucleotide sequences upstream of the target site and a second amplification product of nucleotide sequences downstream of the target site;

(b) mixing a cassette to be inserted in the target site with the first amplification product of (a), wherein said cassette comprises a first strand comprising at its 5' end nucleotide sequences which overlap with nucleotides of the first amplification product and at its 3' end nucleotide sequences which overlap with nucleotides of the second amplification product;

(c) amplifying the cassette and the first amplification product of (a), thereby forming a first fusion product consisting of the first amplification product fused to the 5' end of the first strand of the cassette;

(d) mixing the cassette to be inserted in the target site with the second amplification product of (a);

(e) amplifying the cassette and the second amplification product of (a), thereby forming a second fusion product consisting of the second amplification product fused to the 3' end of the first strand of the cassette; and

(f) mixing the first and second fusion products of (c) and (e) and amplifying the fusion products via polymerase chain reaction, thereby producing a nucleic acid cassette fusion comprising the cassette in the target site of the selected nucleic acid molecule.

2. The method according to claim 1, further comprising (g) amplifying

the nucleic acid cassette fusion.

3. The method according to claim 1, wherein the amplification step (a) further comprises performing polymerase chain reaction using a first set of primers, P1 and P2, wherein P1 is a forward primer for the region upstream of the target site and P2 is a reverse primer for the region upstream of the target site and further has a sequence which is complementary to the 5' end of the first strand of the cassette.

4. The method according to claim 3, wherein P1 is about 20bp to about 30 bp and P2 is about 30 bp to about 40 bp.

5. The method according to claim 4, wherein P1 is about 20 bp.

6. The method according to claim 4, wherein P2 is about 40 bp.

7. The method according to claim 2, wherein the amplification step (a) further comprises performing polymerase chain reaction using a second set of primers, P3 and P4, wherein P3 is the forward primer for the region downstream of the target site and has a sequence which is complementary to the 3' end of the cassette, and P4 is the reverse primer for the region downstream of the target site.

8. The method according to claim 7, wherein P3 is about 20 bp to about 30 bp and P4 is about 30 bp to about 50 bp.

9. The method according to claim 8, wherein P3 is about 40 bp in length and P4 is about 20 bp in length.

10. The method according to claim 1, further comprising the step of amplifying the cassette prior to mixture with the amplification products of (c) or (e).

11. The method according to claim 1, wherein the amplification step (c) further comprises performing polymerase chain reaction using a set of primers, P1 and R2, wherein P1 is the forward primer for the region upstream of the target site and R2 is a reverse primer for the cassette.

12. The method according to claim 1, wherein the amplification step (d) further comprises performing polymerase chain reaction using a set of primers, R1 and P4, wherein R1 is the forward primer for the cassette and P4 is the reverse primer for the region downstream of the target site.

13. The method according to claim 1, wherein the amplification of (f) further comprises the steps of:

- (i) heating the mixture of (f) for about 5 minutes in the absence of polymerase or primers at about 94EC;
- (ii) cooling the heated mixture of (g) to 50EC over about 30 minutes;
- (iii) maintaining the mixture at about 50EC for at least about 5 minutes;
- (iv) adding a thermostable polymerase to the mixture;
- (v) adding a proof-reading polymerase with 3' exonuclease activity to the mixture;
- (vi) heating the mixture to about 72EC for about 5 minutes; and
- (vii) adding to the mixture primers comprising a 5' forward primer P1 and a 3' reverse primer P4 for the nucleotide sequences downstream of the target site (a) and amplifying using 30 cycles of polymerase chain reaction.

14. The method according to claim 13, wherein said thermostable polymerase is Taq polymerase.

15. The method according to claim 1, wherein said cassette comprises double stranded nucleic acid sequences.
16. The method according to claim 1, wherein said cassette comprises an antibiotic resistance gene.
17. The method according to claim 1, wherein said cassette comprises a DNA sequence selected from the group consisting of promoter, a terminator, and an operator.
18. The method according to claim 1, wherein said cassette comprises a reporter gene.
19. The method according to claim 1, wherein said selected nucleic acid molecule of (a) is a plasmid.
20. The method according to claim 1, wherein said nucleic acid molecule is linear.
21. The method according to claim 1, wherein said nucleic acid sequences are from a gram positive or gram negative bacteria.
22. The method according to claim 21, wherein said nucleic acid sequences are from a Streptococcus or a Staphylococcus bacterium.
23. A nucleic acid-cassette fusion produced according to the method according to claim 1.
24. A method for inserting a cassette into a DNA molecule to produce a

nucleic acid-cassette fusion without requiring ligation. said method comprising the steps of:

(a) providing a selected DNA molecule comprising a first region of DNA sequences upstream of a site targeted for disruption and a second region of DNA sequences downstream of the target site, said first and second region comprising a first strand having a first and second end;

(b) providing a cassette comprising a first strand of DNA, wherein the first strand comprises at its 5' end DNA sequences which overlap with sequences at the second end of the first region, and at its 3' end DNA sequences which overlap with sequences of the first end of the second region;

(c) amplifying the selected DNA sequence using primers for the first and second region, thereby producing amplified first and second regions;

(d) mixing the cassette with the amplified first and second regions;

(e) amplifying the mixture of (d) using polymerase chain reaction, thereby producing without ligation a DNA sequence fusion cassette comprising the first and second regions of the DNA sequence flanking the cassette.

25. The method according to claim 24, wherein the primers for the ends of the first and second regions which overlap with the ends of the cassette contain sequences which are complementary to the sequences of the overlap.

26. The method according to claim 24, wherein the overlap in sequences between the end of the cassette and the second end of the first region is about 10 to about 50 base pairs in length.

27. The method according to claim 24, wherein the overlap in sequences between the end of the cassette and the first end of the second region is about 10 to about 50 base pairs in length.

28. The method according to claim 24, wherein the amplifying step (e) further comprises the steps of:

- (i) heating the mixture of (d) for about 5 minutes in the absence of polymerase or primers at about 94EC;
- (ii) cooling the heated mixture of (i) to 50EC over about 30 minutes;
- (iii) maintaining the mixture at about 50EC for about 5 minutes;
- (iv) adding a thermostable polymerase to the mixture;
- (v) adding a proof-reading polymerase with 3' exonuclease activity to the mixture;
- (vi) heating the mixture to about 72EC for about 5 minutes; and
- (vii) adding to the mixture primers comprising a 5' forward primer P1 and a 3' reverse primer P4 for the nucleotide sequence region downstream of the target site.

29. A method for inserting a cassette into a DNA molecule to produce a nucleic acid-cassette fusion without requiring ligation, said method comprising the steps of:

- (a) providing a first region of DNA sequences and a second region of DNA sequences, said first and second regions each comprising a first strand having a first and second end;
- (b) mixing with the first and second regions a cassette comprising a first strand of DNA, wherein the first strand comprises at its 5' end DNA sequences which overlap with sequences at the second end of the first region, and at its 3' end DNA sequences which overlap with sequences of the first end of the second region;
- (c) mixing the cassette with the first and second regions;
- (d) heating the mixture of (c) for about 5 minutes in the absence of polymerase or primers at about 94EC;
- (e) cooling the heated mixture of (i) to 50EC over about 30 minutes;
- (f) maintaining the mixture at about 50EC for about 5 minutes;

- (g) adding a thermostable polymerase to the mixture;
- (h) adding a proof-reading polymerase with 3' exonuclease activity to the mixture;
- (i) heating the mixture to about 72EC for about 5 minutes;
- (j) adding to the mixture primers comprising a 5' forward primer P1 for the first region and a 3' reverse primer P4 for the second region, and
- (k) amplifying the mixture of (j) using polymerase chain reaction, thereby producing without ligation a DNA sequence fusion cassette comprising the first and second regions of the DNA sequence flanking the cassette;

30. A method of high throughput preparation of disrupted Streptococcus DNA sequences without ligation, said method comprising the step of:

- (a) providing a nucleic acid molecule comprising Streptococcus DNA sequences comprising a first region upstream of a site in the Streptococcus DNA targeted for disruption and a second region downstream of the target site, said first and second region each having a first and second end;
- (b) providing a cassette comprising at one end, nucleotide sequences which overlap with nucleotides at the second end of the first region, and at its other end, nucleotides which overlap with nucleotides of the first end of the second region;
- (c) mixing the nucleic acid molecule with primers for the first and second regions in each of the wells of a plate containing a plurality of reaction wells;
- (d) amplifying the first and second regions of the selected Streptococcus DNA sequences;
- (e) mixing the cassette and the amplified first and second regions of the Streptococcus DNA sequences; and
- (f) amplifying the mixture of (e), thereby producing a nucleic acid fusion molecule comprising the first and second regions of the Streptococcus DNA sequence flanking the cassette.

31. The method according to claim 30, wherein the nucleic acid sequence is a plasmid.

32. The method according to claim 30, further comprising the step of incubating the nucleic acid fusion molecules in the presence of *Streptococcus* and detecting the presence of the cassette in the target site.

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Methods for Producing Modified Nucleic Acid Molecules"

the specification of which (check one)

☐ is attached hereto.

☒ was filed on **4 May 2000** as Serial No. **PCT/US00/12103**
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

| Number | Country | Filing Date | Priority Claimed |
|--------|---------|-------------|------------------|
|--------|---------|-------------|------------------|

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

| Application Number | Filing Date |
|--------------------|--------------------|
| 60/133,391 | 10 May 1999 |

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

| Serial No. | Filing Date | Status |
|------------|-------------|--------|
|------------|-------------|--------|


I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Edward R. Gimmi, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-4478.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00
Full Name of Inventor: Alison F. CHALKER

Inventor's Signature: 

Date: 6-26-00

Residence: 137 Havard Drive, College Woods, Trappe, Pennsylvania 19426 PA

Citizenship: United Kingdom

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

2-00
Full Name of Inventor: David J. HOLMES

Inventor's Signature: 

Date: 07.05.00


Residence: 126 Woodmint Drive, West Chester, Pennsylvania 19380 PA

Citizenship: United Kingdom

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

3-00

Full Name of Inventor: Robert Dwayne LUNSFORD

Inventor's Signature: 

Date: 7/5/00


Residence: 2026 Deer Ridge Drive, Pottstown, Pennsylvania 19464 **PA**

Citizenship: United States of America

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

4-00

Full Name of Inventor: James Yigong GE

Inventor's Signature: 

Date: 06/15/2000

Residence: Two Corporate Drive, South San Francisco, California 94080 **CA**

Citizenship: Peoples Republic of China

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

10/009315

SEQUENCE LISTING

<110> CHALKER, ALISON F.
HOLMES, DAVID J.
LUNSFORD, ROBERT DWAYNE
GE, JAMES YIGONG

<120> METHODS FOR PRODUCING MODIFIED NUCLEIC
ACID MOLECULES

<130> GM50049

<140> TO BE ASSIGNED

<141> 2001-11-05

<150> PCT/US00/12103

<151> 2000-05-04

<150> 60/133,391

<151> 1999-05-10

<160> 24

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 24

<212> DNA

<213> Streptococcus pneumoniae

<400> 1

taaggggcta cattgaccga gtgc

24

<210> 2

<211> 45

<212> DNA

<213> Streptococcus pneumoniae

<400> 2

ccgccattct ttgctgtttc gttccagctt ttgccatcag tttct 45

<210> 3

<211> 45

<212> DNA

<213> Streptococcus pneumoniae

<400> 3

ggaaaagttac acgttactaa aggctggggc acgctcattc ttaca 45

<210> 4

<211> 22

<212> DNA

<213> Streptococcus pneumoniae

<400> 4

ttttcatagt gcctccaacc tt 22

<210> 5

<211> 23

<212> DNA

<213> Streptococcus pneumoniae

<400> 5

cttattttta cccatgccct tgt 23

<210> 6

<211> 24

<212> DNA

<213> Streptococcus pneumoniae

<400> 6

caggccatcc ctccttgga aata 24

<210> 7

<211> 21

<212> DNA

<213> Streptococcus pneumoniae

<400> 7

cgaaacagca aagaatggcg g

21

<210> 8

<211> 22

<212> DNA

<213> Streptococcus pneumoniae

<400> 8

ccttttagtaa cgtgtaactt tc

22

<210> 9

<211> 23

<212> DNA

<213> Streptococcus pneumoniae

<400> 9

taaggggcta cattgaccag ttc

23

<210> 10

<211> 44

<212> DNA

<213> Streptococcus pneumoniae

<400> 10

cgcgcattct ttgctgtttc gttccagctt ttgccatcag tttc

44

<210> 11

<211> 44

<212> DNA

<213> Streptococcus pneumoniae

<400> 11

ggaaagttac acgttactaa aggctggggc acgctcattc ttac

44

<210> 12

<211> 22

<212> DNA

<213> Streptococcus pneumoniae

<400> 12

ttttcatagt gcctccaacc tt

22

<210> 13

<211> 24

<212> DNA

<213> Streptococcus pneumoniae

<400> 13

cttattttta cccatgccct tgta

24

<210> 14

<211> 24

<212> DNA

<213> Streptococcus pneumoniae

<400> 14

caggccatcc ctccttgga aata

24

<210> 15

<211> 21

<212> DNA

<213> Streptococcus pneumoniae

<400> 15

cgaaacagca aagaatggcg g

21

<210> 16

<211> 23

<212> DNA

<213> Streptococcus pneumoniae

<400> 16

ccttttagtaa cgtgtaactt tcc

23

<210> 17

<211> 29

<212> DNA

<213> Streptococcus aureus

<400> 17

cgcggtatcct gttgtagatt tagtgaccg 29

<210> 18

<211> 40

<212> DNA

<213> Streptococcus aureus

<400> 18

cgggatacaa agacataatc ttccctacat ttggtctacc 40

<210> 19

<211> 40

<212> DNA

<213> Streptococcus aureus

<400> 19

gtaagttaag ggatgcataa tggttatggt gaagaccaag 40

<210> 20

<211> 29

<212> DNA

<213> Streptococcus aureus

<400> 20

cgcggtatcct cagcttgtgt gtcattacc 29

<210> 21

<211> 20

<212> DNA

<213> Streptococcus aureus

<400> 21

atcttttagaa gcctcttgcc 20

<210> 22

<211> 20

<212> DNA

<213> Streptococcus aureus

<400> 22

atcttttagaa gcctcttgcc

20

<210> 23

<211> 20

<212> DNA

<213> Streptococcus aureus

<400> 23

gattatgtct ttgtatcccg

20

<210> 24

<211> 20

<212> DNA

<213> Streptococcus aureus

<400> 24

ttatgcatcc cttaacttac

20